EMEA-003581-PIP01-24
Submitted by Anonymous (not verified) on 26 June 2025 - 15:04
EMEA-003581-PIP01-24
EMEA-003525-PIP01-23
Submitted by Anonymous (not verified) on 26 June 2025 - 15:02
EMEA-003525-PIP01-23
EMEA-003463-PIP01-23
Submitted by Anonymous (not verified) on 26 June 2025 - 15:01
EMEA-003463-PIP01-23
EMEA-003459-PIP01-23
Submitted by Anonymous (not verified) on 26 June 2025 - 15:00
EMEA-003459-PIP01-23
Referral: Ipidacrine-containing medicinal products, ipidacrine Article 31 referrals Procedure started, 26/06/2025
Submitted by Anonymous (not verified) on 26 June 2025 - 14:58
Referral: Ipidacrine-containing medicinal products, ipidacrine Article 31 referrals Procedure started, 26/06/2025
Newsletters
Submitted by Anonymous (not verified) on 26 June 2025 - 14:57
Newsletters
PRIME: 5 years' experience
Submitted by Anonymous (not verified) on 26 June 2025 - 14:49
PRIME: 5 years' experience
Human medicines European public assessment report (EPAR): Pavblu, aflibercept, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 26 June 2025 - 13:32
Human medicines European public assessment report (EPAR): Pavblu, aflibercept, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Phesgo, pertuzumab,trastuzumab, Date of authorisation: 21/12/2020, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 26 June 2025 - 13:28
Human medicines European public assessment report (EPAR): Phesgo, pertuzumab,trastuzumab, Date of authorisation: 21/12/2020, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Date of authorisation: 20/03/2007, Revision: 34, Status: Authorised
Submitted by Anonymous (not verified) on 26 June 2025 - 13:18
Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Date of authorisation: 20/03/2007, Revision: 34, Status: Authorised